FR2912744B1 - Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations. - Google Patents

Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations.

Info

Publication number
FR2912744B1
FR2912744B1 FR0701138A FR0701138A FR2912744B1 FR 2912744 B1 FR2912744 B1 FR 2912744B1 FR 0701138 A FR0701138 A FR 0701138A FR 0701138 A FR0701138 A FR 0701138A FR 2912744 B1 FR2912744 B1 FR 2912744B1
Authority
FR
France
Prior art keywords
pyrrolo
compounds
pyridine compounds
azain
doles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0701138A
Other languages
English (en)
French (fr)
Other versions
FR2912744A1 (fr
Inventor
Laurent Meijer
Benoit Joseph
Francois Liger
Bernard Marquet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR0701138A priority Critical patent/FR2912744B1/fr
Priority to PCT/FR2008/000197 priority patent/WO2008129152A1/fr
Priority to US12/526,446 priority patent/US20100184790A1/en
Priority to JP2009549445A priority patent/JP2010518153A/ja
Priority to EP08775557.5A priority patent/EP2125803B1/fr
Priority to CA002678007A priority patent/CA2678007A1/fr
Publication of FR2912744A1 publication Critical patent/FR2912744A1/fr
Application granted granted Critical
Publication of FR2912744B1 publication Critical patent/FR2912744B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR0701138A 2007-02-16 2007-02-16 Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations. Expired - Fee Related FR2912744B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0701138A FR2912744B1 (fr) 2007-02-16 2007-02-16 Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations.
PCT/FR2008/000197 WO2008129152A1 (fr) 2007-02-16 2008-02-14 Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations
US12/526,446 US20100184790A1 (en) 2007-02-16 2008-02-14 Pyrrolo[2,3-b]pyridine compounds, azaindole compounds used for synthesizing said pyrrolo[2,3-b]pyridine compounds, methods for the production thereof, and uses thereof
JP2009549445A JP2010518153A (ja) 2007-02-16 2008-02-14 ピロロ[2,3−b]ピリジン化合物、該ピロロ[2,3−b]ピリジン化合物を合成するために用いられるアザインドール化合物、それらの製造方法、及びそれらの使用
EP08775557.5A EP2125803B1 (fr) 2007-02-16 2008-02-14 Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations
CA002678007A CA2678007A1 (fr) 2007-02-16 2008-02-14 Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0701138A FR2912744B1 (fr) 2007-02-16 2007-02-16 Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations.

Publications (2)

Publication Number Publication Date
FR2912744A1 FR2912744A1 (fr) 2008-08-22
FR2912744B1 true FR2912744B1 (fr) 2012-09-07

Family

ID=38515529

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0701138A Expired - Fee Related FR2912744B1 (fr) 2007-02-16 2007-02-16 Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations.

Country Status (6)

Country Link
US (1) US20100184790A1 (enExample)
EP (1) EP2125803B1 (enExample)
JP (1) JP2010518153A (enExample)
CA (1) CA2678007A1 (enExample)
FR (1) FR2912744B1 (enExample)
WO (1) WO2008129152A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110201599A1 (en) * 2008-07-03 2011-08-18 Exelixis, Inc. CDK Modulators
CN102471339A (zh) * 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡啶抑制剂
CA2878054C (en) 2012-06-29 2018-09-11 Pfizer Inc. Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
FR2999575A1 (fr) 2012-12-18 2014-06-20 Centre Nat Rech Scient 3,5-diaryl-azaindoles comme inhibiteurs de la proteine dyrk1a pour le traitement des deficiences cognitives liees au syndrome de down et a la maladie d'alzheimer
WO2015092592A1 (en) * 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
TW201613919A (en) 2014-07-02 2016-04-16 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
AU2016322813B2 (en) 2015-09-14 2021-04-01 Pfizer Inc. Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
FR3041640B1 (fr) * 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
EP3383875B1 (en) 2015-11-30 2022-02-09 Council Of Scientific & Industrial Research 3-pyrimidinyl pyrrolo [2,3-b] pyridine as anticancer agents and the process for the preparation thereof
US10703757B2 (en) 2016-12-23 2020-07-07 Plexxikon Inc. Compounds and methods for CDK8 modulation and indications therefor
CN110662745B (zh) * 2017-03-23 2021-08-03 大邱庆北尖端医疗产业振兴财团 吡咯并吡啶衍生物、其制备方法、和用于预防或治疗蛋白激酶相关疾病的药物组合物
CN111278840B (zh) * 2017-08-18 2023-11-17 癌症研究科技有限公司 吡咯并[2,3-b]吡啶化合物及其治疗癌症的用途
CN110759892B (zh) * 2018-07-26 2022-09-13 南开大学 Meridianin类衍生物及其制备和在防治植物病毒病菌病中的应用
CN109096257B (zh) * 2018-08-09 2020-02-21 山东博苑医药化学有限公司 Meridianin类生物碱及其衍生物在防治植物病毒病菌病中的应用
US12240844B2 (en) 2019-01-18 2025-03-04 Voronoi, Inc. Pyrrolopyridine derivative and use thereof in prevention and treatment of protein kinase-related disease
CN109879874A (zh) * 2019-03-05 2019-06-14 常州大学 一种Meriolin的合成方法
KR20220081631A (ko) 2020-12-09 2022-06-16 보로노이 주식회사 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
US20240261297A1 (en) * 2021-05-20 2024-08-08 St. John's Cancer Institute Anti-cdk inhibitors for cancer treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855205B2 (en) * 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
KR20080016643A (ko) * 2005-05-16 2008-02-21 아이알엠 엘엘씨 단백질 키나제 억제제로서의 피롤로피리딘 유도체
AU2006319233B9 (en) * 2005-11-30 2011-09-29 F. Hoffmann-La Roche Ag 3-amino-2-arylpropyl azaindoles and uses thereof

Also Published As

Publication number Publication date
US20100184790A1 (en) 2010-07-22
WO2008129152A1 (fr) 2008-10-30
EP2125803A1 (fr) 2009-12-02
EP2125803B1 (fr) 2013-04-10
FR2912744A1 (fr) 2008-08-22
CA2678007A1 (fr) 2008-10-30
JP2010518153A (ja) 2010-05-27

Similar Documents

Publication Publication Date Title
FR2912744B1 (fr) Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations.
BRPI0822237A2 (pt) Compostos de imidazo [1,2-a] piridina
IL201009A0 (en) Pyrazolo pyridine derivatives, compositions comprising the same and uses thereof
IL204720A0 (en) Imidazo [1, 2 - a] pyridine derivatives useful as alk inhibitors
IL211892A0 (en) Pyrazolo pyridine derivatives, compositions comprising the same and uses thereof
EP1923359A4 (en) FLUID AND MANUFACTURING METHOD THEREFOR
BR112013015959A2 (pt) Derivados de 2-arilimidazo [1,2-b] piridazina, 2- fenilimidazo [1,2-a] piridina, e 2-fenilimidazo [1,2-a] pirazina.
IL205458A0 (en) [1h - pyrazolo [3, 4 - b] pyridine- 4 - yl] - phenyl or - pyridin - 2 - yl derivatives,processes for producing the same and uses thereof
ZA201204028B (en) Imidazo[1.2-a]pyridine compounds, sysnthesis thereof, and methods of using same
EP2067782A4 (en) Heterocyclic derivative, tetrahalogenated phenylenediamine, and process for its preparation
DK2137184T3 (da) Imidazo[1,2-a]pyridinforbindelser som receptor-tyrosinkinaseinhibitorer
IL211891A0 (en) Pyrazolo pyridine derivatives, compositions comprising the same and uses thereof
EP1638993A4 (en) IMMUNOMODULATING COMPOSITIONS, APPLICATIONS THEREOF AND METHOD FOR THE PRODUCTION THEREOF
BRPI0811718A2 (pt) Derivados de 3,3-espiroindolinona
EP1723161A4 (en) RADIOACTIVELY MARKED COMPOUNDS AND COMPOSITIONS, PRECURSORS AND METHOD FOR THE PRODUCTION THEREOF
NO20051322D0 (no) System for tetting av ringrom i bronnhullene
IL204746A0 (en) Pyridine derivatives useful as glucokinase activators
DE602008005634D1 (de) 1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate
FI20075465A0 (fi) Talteenottomenetelmä
DK2124944T3 (da) Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer
EP2154736A4 (en) THERMOELECTRIC CONVERSION ELEMENT AND METHOD FOR PRODUCING THE THERMOELECTRIC CONVERSION ELEMENT
ZA201000107B (en) Pyrimidine derivatives 934
BRPI0914665A2 (pt) derivados de pirimido[2,1-a]isoquinolin-4-ona substituída
PT1994005E (pt) Derivados da tetra-hidronaftalina, processos para a sua produção e a sua utilização como anti-inflamatórios
EP1814892A4 (en) METAL-ORGANIC COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF

Legal Events

Date Code Title Description
TQ Partial transmission of property
ST Notification of lapse

Effective date: 20141031